CoChat

Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model

Open access
Li, Melody, Jancovski, Nikola, Jafar-Nejad, Paymaan, Burbano, Lisseth E., Rollo, Ben, Richards, Kay, Drew, Lisa, Sedo, Alicia, Heighway, Jacqueline, Pachernegg, Svenja, Soriano, Armand, Jia, Linghan, Blackburn, Todd, Roberts, Blaine, Nemiroff, Alex, Dalby, Kelley, Maljevic, Snezana, Reid, Christopher A., Rigo, Frank, Petrou, Steven · 2021 · Journal of Clinical Investigation

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

De novo variation in SCN2A can give rise to severe childhood disorders. Biophysical gain of function in SCN2A is seen in some patients with early seizure onset developmental and epileptic encephalopathy (DEE). In these cases, targeted reduction in SCN2A expression could substantially improve clinical outcomes. We tested this theory by central administration of a gapmer antisense oligonucleotide (ASO) targeting Scn2a mRNA in a mouse model of Scn2a early seizure onset DEE (Q/+ mice). Untreated Q/+ mice presented with spontaneous seizures at P1 and did not survive beyond P30. Administration of the ASO to Q/+ mice reduced spontaneous seizures and significantly extended life span. Across a range of behavioral tests, Scn2a ASO-treated Q/+ mice were largely indistinguishable from WT mice, suggesting treatment is well tolerated. A human SCN2A gapmer ASO could likewise impact the lives of patients with SCN2A gain-of-function DEE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci152079

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 41 · Cited by 115

Metadata

Authors
Li, M., Jancovski, N., Jafar-Nejad, P., Burbano, L. E., Rollo, B., Richards, K., Drew, L., Sedo, A., Heighway, J., Pachernegg, S., Soriano, A., Jia, L., Blackburn, T., Roberts, B., Nemiroff, A., Dalby, K., Maljevic, S., Reid, C. A., Rigo, F., & Petrou, S.
Affiliations
  • Florey Institute of Neuroscience and Mental Health (AU)
  • Ionis Pharmaceuticals (United States) (US)
  • Praxis Precision Medicines Inc. (United States) (US)
Venue
Journal of Clinical Investigation
Published
2021-12-01
Volume
131
Issue
23
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W3215665120
Cited by
115
References
41
Citations by year
2026: 22 · 2025: 26 · 2024: 25 · 2023: 23 · 2022: 15 · 2021: 3
FWCI
11.83
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Health and Medical Research Council (10915693, GNT1005050)
  • RogCon Biosciences (N/A)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
antisense therapy, gapmer, SCN2A, developmental and epileptic encephalopathy, seizures, lifespan extension, sodium channels, gene expression reduction, mouse model
MeSH terms
Gain of Function Mutation, Animals, Behavior, Animal, Biophysics, Disease Models, Animal, Electroencephalography, Epilepsy, Humans, Longevity, Male, Movement, Mutation, Phenotype, RNA, Messenger, Seizures, Oligonucleotides, Antisense, Maze Learning, Mice, NAV1.2 Voltage-Gated Sodium Channel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model. https://app.cochat.ai/papers/10.1172/jci152079
The paper
Li, M., Jancovski, N., Jafar-Nejad, P., Burbano, L. E., Rollo, B., Richards, K., Drew, L., Sedo, A., Heighway, J., Pachernegg, S., Soriano, A., Jia, L., Blackburn, T., Roberts, B., Nemiroff, A., Dalby, K., Maljevic, S., Reid, C. A., Rigo, F., & Petrou, S. (2021). Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model. Journal of Clinical Investigation. https://doi.org/10.1172/jci152079

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.